APO Research
Talk to an analyst

APO RESEARCH · REPORT

IL-23 Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global IL-23 Receptor Antagonist Market Analysis and Forecast 2026-2032

27 December 2025196 pages

Choose your research edition.

Industry ResearchIL-23 Receptor Antagonist Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-23 Receptor Antagonist Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal IL-23 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-23 Receptor Antagonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-23 Receptor Antagonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global IL-23 Receptor Antagonist market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of IL-23 Receptor Antagonist include Qyuns Therapeutics, China Medical System, Huadong Medicine, Bio-Thera Solutions, Teva, Sun Pharma, Sandoz, Samsung Bioepis and Janssen Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for IL-23 Receptor Antagonist, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of IL-23 Receptor Antagonist, also provides the sales of main regions and countries. Of the upcoming market potential for IL-23 Receptor Antagonist, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the IL-23 Receptor Antagonist sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global IL-23 Receptor Antagonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for IL-23 Receptor Antagonist sales, projected growth trends, production technology, application and end-user industry.

IL-23 Receptor Antagonist Segment by Company

Qyuns Therapeutics

China Medical System

Huadong Medicine

Bio-Thera Solutions

Teva

Sun Pharma

Sandoz

Samsung Bioepis

Janssen Pharmaceuticals

Eli Lilly

Celltrion

Biocon Biologics

Amgen

Almirall

AbbVie Biotechnology

IL-23 Receptor Antagonist Segment by Type

Briakinumab

Guselkumab

Mirikizumab

Risankizumab

Tildrakizumab

Ustekinumab

Other

IL-23 Receptor Antagonist Segment by Application

Plaque Psoriasis

Crohn's Disease

Psoriatic Arthritis

Other

IL-23 Receptor Antagonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-23 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-23 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-23 Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of IL-23 Receptor Antagonist in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of IL-23 Receptor Antagonist manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IL-23 Receptor Antagonist sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global IL-23 Receptor Antagonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Briakinumab Major Manufacturers Table 3. Guselkumab Major Manufacturers Table 4. Mirikizumab Major Manufacturers Table 5. Risankizumab Major Manufacturers Table 6. Tildrakizumab Major Manufacturers Table 7. Ustekinumab Major Manufacturers Table 8. Other Major Manufacturers Table 9. Global IL-23 Receptor Antagonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Plaque Psoriasis Major Manufacturers Table 11. Crohn's Disease Major Manufacturers Table 12. Psoriatic Arthritis Major Manufacturers Table 13. Other Major Manufacturers Table 14. IL-23 Receptor Antagonist Industry Trends Table 15. IL-23 Receptor Antagonist Industry Drivers Table 16. IL-23 Receptor Antagonist Industry Opportunities and Challenges Table 17. IL-23 Receptor Antagonist Industry Restraints Table 18. Global IL-23 Receptor Antagonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global IL-23 Receptor Antagonist Revenue by Region (2021-2026) & (US$ Million) Table 20. Global IL-23 Receptor Antagonist Revenue by Region (2027-2032) & (US$ Million) Table 21. Global IL-23 Receptor Antagonist Revenue Market Share by Region (2021-2026) Table 22. Global IL-23 Receptor Antagonist Revenue Market Share by Region (2027-2032) Table 23. Global IL-23 Receptor Antagonist Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 24. Global IL-23 Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 25. Global IL-23 Receptor Antagonist Sales by Region (2027-2032) & (K Units) Table 26. Global IL-23 Receptor Antagonist Sales Market Share by Region (2021-2026) Table 27. Global IL-23 Receptor Antagonist Sales Market Share by Region (2027-2032) Table 28. Global IL-23 Receptor Antagonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global IL-23 Receptor Antagonist Revenue Market Share by Manufacturers (2021-2026) Table 30. Global IL-23 Receptor Antagonist Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global IL-23 Receptor Antagonist Sales Market Share by Manufacturers (2021-2026) Table 32. Global IL-23 Receptor Antagonist Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 33. Global IL-23 Receptor Antagonist Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global IL-23 Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global IL-23 Receptor Antagonist Manufacturers, Product Type & Application Table 36. Global IL-23 Receptor Antagonist Manufacturers' Establishment Date Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global IL-23 Receptor Antagonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global IL-23 Receptor Antagonist Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 41. Global IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 42. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2026) Table 43. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2027-2032) Table 44. Global IL-23 Receptor Antagonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 45. Global IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 46. Global IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 47. Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2026) Table 48. Global IL-23 Receptor Antagonist Sales Market Share by Type (2027-2032) Table 49. Global IL-23 Receptor Antagonist Price by Type (2021-2026) & (US$/Unit) Table 50. Global IL-23 Receptor Antagonist Price by Type (2027-2032) & (US$/Unit) Table 51. Global IL-23 Receptor Antagonist Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 53. Global IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 54. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2026) Table 55. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2027-2032) Table 56. Global IL-23 Receptor Antagonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 57. Global IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 58. Global IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 59. Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2026) Table 60. Global IL-23 Receptor Antagonist Sales Market Share by Application (2027-2032) Table 61. Global IL-23 Receptor Antagonist Price by Application (2021-2026) & (US$/Unit) Table 62. Global IL-23 Receptor Antagonist Price by Application (2027-2032) & (US$/Unit) Table 63. Qyuns Therapeutics Company Information Table 64. Qyuns Therapeutics Business Overview Table 65. Qyuns Therapeutics IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio Table 67. Qyuns Therapeutics Recent Development Table 68. China Medical System Company Information Table 69. China Medical System Business Overview Table 70. China Medical System IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. China Medical System IL-23 Receptor Antagonist Product Portfolio Table 72. China Medical System Recent Development Table 73. Huadong Medicine Company Information Table 74. Huadong Medicine Business Overview Table 75. Huadong Medicine IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Huadong Medicine IL-23 Receptor Antagonist Product Portfolio Table 77. Huadong Medicine Recent Development Table 78. Bio-Thera Solutions Company Information Table 79. Bio-Thera Solutions Business Overview Table 80. Bio-Thera Solutions IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio Table 82. Bio-Thera Solutions Recent Development Table 83. Teva Company Information Table 84. Teva Business Overview Table 85. Teva IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Teva IL-23 Receptor Antagonist Product Portfolio Table 87. Teva Recent Development Table 88. Sun Pharma Company Information Table 89. Sun Pharma Business Overview Table 90. Sun Pharma IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sun Pharma IL-23 Receptor Antagonist Product Portfolio Table 92. Sun Pharma Recent Development Table 93. Sandoz Company Information Table 94. Sandoz Business Overview Table 95. Sandoz IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sandoz IL-23 Receptor Antagonist Product Portfolio Table 97. Sandoz Recent Development Table 98. Samsung Bioepis Company Information Table 99. Samsung Bioepis Business Overview Table 100. Samsung Bioepis IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio Table 102. Samsung Bioepis Recent Development Table 103. Janssen Pharmaceuticals Company Information Table 104. Janssen Pharmaceuticals Business Overview Table 105. Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio Table 107. Janssen Pharmaceuticals Recent Development Table 108. Eli Lilly Company Information Table 109. Eli Lilly Business Overview Table 110. Eli Lilly IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Eli Lilly IL-23 Receptor Antagonist Product Portfolio Table 112. Eli Lilly Recent Development Table 113. Celltrion Company Information Table 114. Celltrion Business Overview Table 115. Celltrion IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Celltrion IL-23 Receptor Antagonist Product Portfolio Table 117. Celltrion Recent Development Table 118. Biocon Biologics Company Information Table 119. Biocon Biologics Business Overview Table 120. Biocon Biologics IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Biocon Biologics IL-23 Receptor Antagonist Product Portfolio Table 122. Biocon Biologics Recent Development Table 123. Amgen Company Information Table 124. Amgen Business Overview Table 125. Amgen IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Amgen IL-23 Receptor Antagonist Product Portfolio Table 127. Amgen Recent Development Table 128. Almirall Company Information Table 129. Almirall Business Overview Table 130. Almirall IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Almirall IL-23 Receptor Antagonist Product Portfolio Table 132. Almirall Recent Development Table 133. AbbVie Biotechnology Company Information Table 134. AbbVie Biotechnology Business Overview Table 135. AbbVie Biotechnology IL-23 Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio Table 137. AbbVie Biotechnology Recent Development Table 138. North America IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 139. North America IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 140. North America IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 141. North America IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 142. North America IL-23 Receptor Antagonist Sales Price by Type (2021-2026) & (US$/Unit) Table 143. North America IL-23 Receptor Antagonist Sales Price by Type (2027-2032) & (US$/Unit) Table 144. North America IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 145. North America IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 146. North America IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 147. North America IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 148. North America IL-23 Receptor Antagonist Sales Price by Application (2021-2026) & (US$/Unit) Table 149. North America IL-23 Receptor Antagonist Sales Price by Application (2027-2032) & (US$/Unit) Table 150. North America IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. North America IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 152. North America IL-23 Receptor Antagonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 153. North America IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 154. North America IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 155. North America IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 156. North America IL-23 Receptor Antagonist Sales Price by Country (2021-2026) & (US$/Unit) Table 157. North America IL-23 Receptor Antagonist Sales Price by Country (2027-2032) & (US$/Unit) Table 158. United States IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 159. Canada IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 160. Mexico IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 161. Europe IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 162. Europe IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 163. Europe IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 164. Europe IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 165. Europe IL-23 Receptor Antagonist Sales Price by Type (2021-2026) & (US$/Unit) Table 166. Europe IL-23 Receptor Antagonist Sales Price by Type (2027-2032) & (US$/Unit) Table 167. Europe IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 168. Europe IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 169. Europe IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 170. Europe IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 171. Europe IL-23 Receptor Antagonist Sales Price by Application (2021-2026) & (US$/Unit) Table 172. Europe IL-23 Receptor Antagonist Sales Price by Application (2027-2032) & (US$/Unit) Table 173. Europe IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Europe IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. Europe IL-23 Receptor Antagonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. Europe IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 177. Europe IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 178. Europe IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 179. Europe IL-23 Receptor Antagonist Sales Price by Country (2021-2026) & (US$/Unit) Table 180. Europe IL-23 Receptor Antagonist Sales Price by Country (2027-2032) & (US$/Unit) Table 181. Germany IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 182. France IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 183. U.K. IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 184. Italy IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 185. Russia IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 186. Spain IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 187. Netherlands IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 188. Switzerland IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 189. Sweden IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 190. Poland IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 191. China IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 192. China IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 193. China IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 194. China IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 195. China IL-23 Receptor Antagonist Sales Price by Type (2021-2026) & (US$/Unit) Table 196. China IL-23 Receptor Antagonist Sales Price by Type (2027-2032) & (US$/Unit) Table 197. China IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 198. China IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 199. China IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 200. China IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 201. China IL-23 Receptor Antagonist Sales Price by Application (2021-2026) & (US$/Unit) Table 202. China IL-23 Receptor Antagonist Sales Price by Application (2027-2032) & (US$/Unit) Table 203. Asia IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 204. Asia IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 205. Asia IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 206. Asia IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 207. Asia IL-23 Receptor Antagonist Sales Price by Type (2021-2026) & (US$/Unit) Table 208. Asia IL-23 Receptor Antagonist Sales Price by Type (2027-2032) & (US$/Unit) Table 209. Asia IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 210. Asia IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 211. Asia IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 212. Asia IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 213. Asia IL-23 Receptor Antagonist Sales Price by Application (2021-2026) & (US$/Unit) Table 214. Asia IL-23 Receptor Antagonist Sales Price by Application (2027-2032) & (US$/Unit) Table 215. Asia IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 216. Asia IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 217. Asia IL-23 Receptor Antagonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 218. Asia IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 219. Asia IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 220. Asia IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 221. Asia IL-23 Receptor Antagonist Sales Price by Country (2021-2026) & (US$/Unit) Table 222. Asia IL-23 Receptor Antagonist Sales Price by Country (2027-2032) & (US$/Unit) Table 223. Japan IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 224. South Korea IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 225. India IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 226. Australia IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 227. Taiwan IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 228. Southeast Asia IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 229. SAMEA IL-23 Receptor Antagonist Revenue by Type (2021-2026) & (US$ Million) Table 230. SAMEA IL-23 Receptor Antagonist Revenue by Type (2027-2032) & (US$ Million) Table 231. SAMEA IL-23 Receptor Antagonist Sales by Type (2021-2026) & (K Units) Table 232. SAMEA IL-23 Receptor Antagonist Sales by Type (2027-2032) & (K Units) Table 233. SAMEA IL-23 Receptor Antagonist Sales Price by Type (2021-2026) & (US$/Unit) Table 234. SAMEA IL-23 Receptor Antagonist Sales Price by Type (2027-2032) & (US$/Unit) Table 235. SAMEA IL-23 Receptor Antagonist Revenue by Application (2021-2026) & (US$ Million) Table 236. SAMEA IL-23 Receptor Antagonist Revenue by Application (2027-2032) & (US$ Million) Table 237. SAMEA IL-23 Receptor Antagonist Sales by Application (2021-2026) & (K Units) Table 238. SAMEA IL-23 Receptor Antagonist Sales by Application (2027-2032) & (K Units) Table 239. SAMEA IL-23 Receptor Antagonist Sales Price by Application (2021-2026) & (US$/Unit) Table 240. SAMEA IL-23 Receptor Antagonist Sales Price by Application (2027-2032) & (US$/Unit) Table 241. SAMEA IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 242. SAMEA IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 243. SAMEA IL-23 Receptor Antagonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 244. SAMEA IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 245. SAMEA IL-23 Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 246. SAMEA IL-23 Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 247. SAMEA IL-23 Receptor Antagonist Sales Price by Country (2021-2026) & (US$/Unit) Table 248. SAMEA IL-23 Receptor Antagonist Sales Price by Country (2027-2032) & (US$/Unit) Table 249. Brazil IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 250. Argentina IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 251. Chile IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 252. Colombia IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 253. Peru IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 254. Saudi Arabia IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 255. Israel IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 256. UAE IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 257. Turkey IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 258. Iran IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 259. Egypt IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Table 260. Key Raw Materials Table 261. Raw Materials Key Suppliers Table 262. IL-23 Receptor Antagonist Distributors List Table 263. IL-23 Receptor Antagonist Customers List Table 264. Research Programs/Design for This Report Table 265. Authors List of This Report Table 266. Secondary Sources Table 267. Primary Sources List of Figures Figure 1. IL-23 Receptor Antagonist Image Figure 2. Global IL-23 Receptor Antagonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-23 Receptor Antagonist Market Size Share 2021 VS 2025 VS 2032 Figure 4. Briakinumab Image Figure 5. Guselkumab Image Figure 6. Mirikizumab Image Figure 7. Risankizumab Image Figure 8. Tildrakizumab Image Figure 9. Ustekinumab Image Figure 10. Other Image Figure 11. Global IL-23 Receptor Antagonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global IL-23 Receptor Antagonist Market Size Share 2021 VS 2025 VS 2032 Figure 13. Plaque Psoriasis Image Figure 14. Crohn's Disease Image Figure 15. Psoriatic Arthritis Image Figure 16. Other Image Figure 17. Global IL-23 Receptor Antagonist Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global IL-23 Receptor Antagonist Revenue (2021-2032) & (US$ Million) Figure 19. Global IL-23 Receptor Antagonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global IL-23 Receptor Antagonist Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global IL-23 Receptor Antagonist Revenue Market Share by Region (2021-2032) Figure 22. Global IL-23 Receptor Antagonist Sales (2021-2032) & (K Units) Figure 23. Global IL-23 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 24. Global IL-23 Receptor Antagonist Sales Market Share by Region (2021-2032) Figure 25. US & Canada & Mexico IL-23 Receptor Antagonist Sales YoY (2021-2032) & (K Units) Figure 26. Europe IL-23 Receptor Antagonist Sales YoY (2021-2032) & (K Units) Figure 27. China IL-23 Receptor Antagonist Sales YoY (2021-2032) & (K Units) Figure 28. Asia (Excluding China) IL-23 Receptor Antagonist Sales YoY (2021-2032) & (K Units) Figure 29. South America, Middle East and Africa IL-23 Receptor Antagonist Sales YoY (2021-2032) & (K Units) Figure 30. Global IL-23 Receptor Antagonist Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global IL-23 Receptor Antagonist Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global IL-23 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global IL-23 Receptor Antagonist Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2032) Figure 36. Global IL-23 Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global IL-23 Receptor Antagonist Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 38. Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2032) Figure 39. Global IL-23 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 40. Global IL-23 Receptor Antagonist Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2032) Figure 42. Global IL-23 Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 43. Global IL-23 Receptor Antagonist Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 44. Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2032) Figure 45. North America IL-23 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 46. North America IL-23 Receptor Antagonist Sales Share by Type (2021-2032) Figure 47. North America IL-23 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 48. North America IL-23 Receptor Antagonist Sales Share by Application (2021-2032) Figure 49. North America IL-23 Receptor Antagonist Revenue Share by Country (2021-2032) Figure 50. North America IL-23 Receptor Antagonist Sales Share by Country (2021-2032) Figure 51. Europe IL-23 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 52. Europe IL-23 Receptor Antagonist Sales Share by Type (2021-2032) Figure 53. Europe IL-23 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 54. Europe IL-23 Receptor Antagonist Sales Share by Application (2021-2032) Figure 55. Europe IL-23 Receptor Antagonist Revenue Share by Country (2021-2032) Figure 56. Europe IL-23 Receptor Antagonist Sales Share by Country (2021-2032) Figure 57. China IL-23 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 58. China IL-23 Receptor Antagonist Sales Share by Type (2021-2032) Figure 59. China IL-23 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 60. China IL-23 Receptor Antagonist Sales Share by Application (2021-2032) Figure 61. Asia IL-23 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 62. Asia IL-23 Receptor Antagonist Sales Share by Type (2021-2032) Figure 63. Asia IL-23 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 64. Asia IL-23 Receptor Antagonist Sales Share by Application (2021-2032) Figure 65. Asia IL-23 Receptor Antagonist Revenue Share by Country (2021-2032) Figure 66. Asia IL-23 Receptor Antagonist Sales Share by Country (2021-2032) Figure 67. SAMEA IL-23 Receptor Antagonist Revenue Share by Type (2021-2032) Figure 68. SAMEA IL-23 Receptor Antagonist Sales Share by Type (2021-2032) Figure 69. SAMEA IL-23 Receptor Antagonist Revenue Share by Application (2021-2032) Figure 70. SAMEA IL-23 Receptor Antagonist Sales Share by Application (2021-2032) Figure 71. SAMEA IL-23 Receptor Antagonist Revenue Share by Country (2021-2032) Figure 72. SAMEA IL-23 Receptor Antagonist Sales Share by Country (2021-2032) Figure 73. IL-23 Receptor Antagonist Value Chain Figure 74. Manufacturing Cost Structure Figure 75. IL-23 Receptor Antagonist Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Briakinumab
  • Guselkumab
  • Mirikizumab
  • Risankizumab
  • Tildrakizumab
  • Ustekinumab
  • Other
Applications
  • Plaque Psoriasis
  • Crohn's Disease
  • Psoriatic Arthritis
  • Other
Companies covered
  • Qyuns Therapeutics
  • China Medical System
  • Huadong Medicine
  • Bio-Thera Solutions
  • Teva
  • Sun Pharma
  • Sandoz
  • Samsung Bioepis
  • Janssen Pharmaceuticals
  • Eli Lilly
  • Celltrion
  • Biocon Biologics
  • Amgen
  • Almirall
  • AbbVie Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 IL-23 Receptor Antagonist Market by Type
  3. 1.2.1 Global IL-23 Receptor Antagonist Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Briakinumab
  5. 1.2.3 Guselkumab
  6. 1.2.4 Mirikizumab
  7. 1.2.5 Risankizumab
  8. 1.2.6 Tildrakizumab
  9. 1.2.7 Ustekinumab
  10. 1.2.8 Other
  11. 1.3 IL-23 Receptor Antagonist Market by Application
  12. 1.3.1 Global IL-23 Receptor Antagonist Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Plaque Psoriasis
  14. 1.3.3 Crohn's Disease
  15. 1.3.4 Psoriatic Arthritis
  16. 1.3.5 Other
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 IL-23 Receptor Antagonist Market Dynamics
  1. 2.1 IL-23 Receptor Antagonist Industry Trends
  2. 2.2 IL-23 Receptor Antagonist Industry Drivers
  3. 2.3 IL-23 Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 IL-23 Receptor Antagonist Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global IL-23 Receptor Antagonist Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global IL-23 Receptor Antagonist Revenue by Region
  3. 3.2.1 Global IL-23 Receptor Antagonist Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global IL-23 Receptor Antagonist Revenue by Region (2021-2026)
  5. 3.2.3 Global IL-23 Receptor Antagonist Revenue by Region (2027-2032)
  6. 3.2.4 Global IL-23 Receptor Antagonist Revenue Market Share by Region (2021-2032)
  7. 3.3 Global IL-23 Receptor Antagonist Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global IL-23 Receptor Antagonist Sales by Region
  9. 3.4.1 Global IL-23 Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global IL-23 Receptor Antagonist Sales by Region (2021-2026)
  11. 3.4.3 Global IL-23 Receptor Antagonist Sales by Region (2027-2032)
  12. 3.4.4 Global IL-23 Receptor Antagonist Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global IL-23 Receptor Antagonist Revenue by Manufacturers
  2. 4.1.1 Global IL-23 Receptor Antagonist Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global IL-23 Receptor Antagonist Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global IL-23 Receptor Antagonist Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global IL-23 Receptor Antagonist Sales by Manufacturers
  6. 4.2.1 Global IL-23 Receptor Antagonist Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global IL-23 Receptor Antagonist Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global IL-23 Receptor Antagonist Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global IL-23 Receptor Antagonist Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global IL-23 Receptor Antagonist Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global IL-23 Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global IL-23 Receptor Antagonist Manufacturers, Product Type & Application
  13. 4.7 Global IL-23 Receptor Antagonist Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global IL-23 Receptor Antagonist Market CR5 and HHI
  16. 4.8.2 2025 IL-23 Receptor Antagonist Tier 1, Tier 2, and Tier 3
5 IL-23 Receptor Antagonist Market by Type
  1. 5.1 Global IL-23 Receptor Antagonist Revenue by Type
  2. 5.1.1 Global IL-23 Receptor Antagonist Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global IL-23 Receptor Antagonist Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global IL-23 Receptor Antagonist Revenue Market Share by Type (2021-2032)
  5. 5.2 Global IL-23 Receptor Antagonist Sales by Type
  6. 5.2.1 Global IL-23 Receptor Antagonist Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global IL-23 Receptor Antagonist Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global IL-23 Receptor Antagonist Sales Market Share by Type (2021-2032)
  9. 5.3 Global IL-23 Receptor Antagonist Price by Type
6 IL-23 Receptor Antagonist Market by Application
  1. 6.1 Global IL-23 Receptor Antagonist Revenue by Application
  2. 6.1.1 Global IL-23 Receptor Antagonist Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global IL-23 Receptor Antagonist Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global IL-23 Receptor Antagonist Revenue Market Share by Application (2021-2032)
  5. 6.2 Global IL-23 Receptor Antagonist Sales by Application
  6. 6.2.1 Global IL-23 Receptor Antagonist Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global IL-23 Receptor Antagonist Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global IL-23 Receptor Antagonist Sales Market Share by Application (2021-2032)
  9. 6.3 Global IL-23 Receptor Antagonist Price by Application
7 Company Profiles
  1. 7.1 Qyuns Therapeutics
  2. 7.1.1 Qyuns Therapeutics Company Information
  3. 7.1.2 Qyuns Therapeutics Business Overview
  4. 7.1.3 Qyuns Therapeutics IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio
  6. 7.1.5 Qyuns Therapeutics Recent Developments
  7. 7.2 China Medical System
  8. 7.2.1 China Medical System Company Information
  9. 7.2.2 China Medical System Business Overview
  10. 7.2.3 China Medical System IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 China Medical System IL-23 Receptor Antagonist Product Portfolio
  12. 7.2.5 China Medical System Recent Developments
  13. 7.3 Huadong Medicine
  14. 7.3.1 Huadong Medicine Company Information
  15. 7.3.2 Huadong Medicine Business Overview
  16. 7.3.3 Huadong Medicine IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Huadong Medicine IL-23 Receptor Antagonist Product Portfolio
  18. 7.3.5 Huadong Medicine Recent Developments
  19. 7.4 Bio-Thera Solutions
  20. 7.4.1 Bio-Thera Solutions Company Information
  21. 7.4.2 Bio-Thera Solutions Business Overview
  22. 7.4.3 Bio-Thera Solutions IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio
  24. 7.4.5 Bio-Thera Solutions Recent Developments
  25. 7.5 Teva
  26. 7.5.1 Teva Company Information
  27. 7.5.2 Teva Business Overview
  28. 7.5.3 Teva IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Teva IL-23 Receptor Antagonist Product Portfolio
  30. 7.5.5 Teva Recent Developments
  31. 7.6 Sun Pharma
  32. 7.6.1 Sun Pharma Company Information
  33. 7.6.2 Sun Pharma Business Overview
  34. 7.6.3 Sun Pharma IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sun Pharma IL-23 Receptor Antagonist Product Portfolio
  36. 7.6.5 Sun Pharma Recent Developments
  37. 7.7 Sandoz
  38. 7.7.1 Sandoz Company Information
  39. 7.7.2 Sandoz Business Overview
  40. 7.7.3 Sandoz IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sandoz IL-23 Receptor Antagonist Product Portfolio
  42. 7.7.5 Sandoz Recent Developments
  43. 7.8 Samsung Bioepis
  44. 7.8.1 Samsung Bioepis Company Information
  45. 7.8.2 Samsung Bioepis Business Overview
  46. 7.8.3 Samsung Bioepis IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio
  48. 7.8.5 Samsung Bioepis Recent Developments
  49. 7.9 Janssen Pharmaceuticals
  50. 7.9.1 Janssen Pharmaceuticals Company Information
  51. 7.9.2 Janssen Pharmaceuticals Business Overview
  52. 7.9.3 Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio
  54. 7.9.5 Janssen Pharmaceuticals Recent Developments
  55. 7.10 Eli Lilly
  56. 7.10.1 Eli Lilly Company Information
  57. 7.10.2 Eli Lilly Business Overview
  58. 7.10.3 Eli Lilly IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Eli Lilly IL-23 Receptor Antagonist Product Portfolio
  60. 7.10.5 Eli Lilly Recent Developments
  61. 7.11 Celltrion
  62. 7.11.1 Celltrion Company Information
  63. 7.11.2 Celltrion Business Overview
  64. 7.11.3 Celltrion IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Celltrion IL-23 Receptor Antagonist Product Portfolio
  66. 7.11.5 Celltrion Recent Developments
  67. 7.12 Biocon Biologics
  68. 7.12.1 Biocon Biologics Company Information
  69. 7.12.2 Biocon Biologics Business Overview
  70. 7.12.3 Biocon Biologics IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Biocon Biologics IL-23 Receptor Antagonist Product Portfolio
  72. 7.12.5 Biocon Biologics Recent Developments
  73. 7.13 Amgen
  74. 7.13.1 Amgen Company Information
  75. 7.13.2 Amgen Business Overview
  76. 7.13.3 Amgen IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Amgen IL-23 Receptor Antagonist Product Portfolio
  78. 7.13.5 Amgen Recent Developments
  79. 7.14 Almirall
  80. 7.14.1 Almirall Company Information
  81. 7.14.2 Almirall Business Overview
  82. 7.14.3 Almirall IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Almirall IL-23 Receptor Antagonist Product Portfolio
  84. 7.14.5 Almirall Recent Developments
  85. 7.15 AbbVie Biotechnology
  86. 7.15.1 AbbVie Biotechnology Company Information
  87. 7.15.2 AbbVie Biotechnology Business Overview
  88. 7.15.3 AbbVie Biotechnology IL-23 Receptor Antagonist Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio
  90. 7.15.5 AbbVie Biotechnology Recent Developments
8 North America
  1. 8.1 North America IL-23 Receptor Antagonist Market Size by Type
  2. 8.1.1 North America IL-23 Receptor Antagonist Revenue by Type (2021-2032)
  3. 8.1.2 North America IL-23 Receptor Antagonist Sales by Type (2021-2032)
  4. 8.1.3 North America IL-23 Receptor Antagonist Price by Type (2021-2032)
  5. 8.2 North America IL-23 Receptor Antagonist Market Size by Application
  6. 8.2.1 North America IL-23 Receptor Antagonist Revenue by Application (2021-2032)
  7. 8.2.2 North America IL-23 Receptor Antagonist Sales by Application (2021-2032)
  8. 8.2.3 North America IL-23 Receptor Antagonist Price by Application (2021-2032)
  9. 8.3 North America IL-23 Receptor Antagonist Market Size by Country
  10. 8.3.1 North America IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America IL-23 Receptor Antagonist Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe IL-23 Receptor Antagonist Market Size by Type
  2. 9.1.1 Europe IL-23 Receptor Antagonist Revenue by Type (2021-2032)
  3. 9.1.2 Europe IL-23 Receptor Antagonist Sales by Type (2021-2032)
  4. 9.1.3 Europe IL-23 Receptor Antagonist Price by Type (2021-2032)
  5. 9.2 Europe IL-23 Receptor Antagonist Market Size by Application
  6. 9.2.1 Europe IL-23 Receptor Antagonist Revenue by Application (2021-2032)
  7. 9.2.2 Europe IL-23 Receptor Antagonist Sales by Application (2021-2032)
  8. 9.2.3 Europe IL-23 Receptor Antagonist Price by Application (2021-2032)
  9. 9.3 Europe IL-23 Receptor Antagonist Market Size by Country
  10. 9.3.1 Europe IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe IL-23 Receptor Antagonist Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China IL-23 Receptor Antagonist Market Size by Type
  2. 10.1.1 China IL-23 Receptor Antagonist Revenue by Type (2021-2032)
  3. 10.1.2 China IL-23 Receptor Antagonist Sales by Type (2021-2032)
  4. 10.1.3 China IL-23 Receptor Antagonist Price by Type (2021-2032)
  5. 10.2 China IL-23 Receptor Antagonist Market Size by Application
  6. 10.2.1 China IL-23 Receptor Antagonist Revenue by Application (2021-2032)
  7. 10.2.2 China IL-23 Receptor Antagonist Sales by Application (2021-2032)
  8. 10.2.3 China IL-23 Receptor Antagonist Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia IL-23 Receptor Antagonist Market Size by Type
  2. 11.1.1 Asia IL-23 Receptor Antagonist Revenue by Type (2021-2032)
  3. 11.1.2 Asia IL-23 Receptor Antagonist Sales by Type (2021-2032)
  4. 11.1.3 Asia IL-23 Receptor Antagonist Price by Type (2021-2032)
  5. 11.2 Asia IL-23 Receptor Antagonist Market Size by Application
  6. 11.2.1 Asia IL-23 Receptor Antagonist Revenue by Application (2021-2032)
  7. 11.2.2 Asia IL-23 Receptor Antagonist Sales by Application (2021-2032)
  8. 11.2.3 Asia IL-23 Receptor Antagonist Price by Application (2021-2032)
  9. 11.3 Asia IL-23 Receptor Antagonist Market Size by Country
  10. 11.3.1 Asia IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia IL-23 Receptor Antagonist Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA IL-23 Receptor Antagonist Market Size by Type
  2. 12.1.1 SAMEA IL-23 Receptor Antagonist Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA IL-23 Receptor Antagonist Sales by Type (2021-2032)
  4. 12.1.3 SAMEA IL-23 Receptor Antagonist Price by Type (2021-2032)
  5. 12.2 SAMEA IL-23 Receptor Antagonist Market Size by Application
  6. 12.2.1 SAMEA IL-23 Receptor Antagonist Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA IL-23 Receptor Antagonist Sales by Application (2021-2032)
  8. 12.2.3 SAMEA IL-23 Receptor Antagonist Price by Application (2021-2032)
  9. 12.3 SAMEA IL-23 Receptor Antagonist Market Size by Country
  10. 12.3.1 SAMEA IL-23 Receptor Antagonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA IL-23 Receptor Antagonist Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA IL-23 Receptor Antagonist Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 IL-23 Receptor Antagonist Value Chain Analysis
  2. 13.1.1 IL-23 Receptor Antagonist Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 IL-23 Receptor Antagonist Production Mode & Process
  6. 13.2 IL-23 Receptor Antagonist Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 IL-23 Receptor Antagonist Distributors
  9. 13.2.3 IL-23 Receptor Antagonist Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst